Objective: Therapies for end-stage renal disease improve quality of life, and survival. In Mexico, clinicians often must choose between different therapies without the availability of comparative outcomes evaluation. The present study evaluates the comparative cost-utility of sirolimus (SIR) versus tacrolimus (TAC) for the primary prevention of graft rejection in renal transplant recipients in Mexico. Methods: We used modeling techniques to estimate the cost-effectiveness of SIR versus TAC to prevent graft rejection in patients with end-stage renal disease in the Mexican setting. The model estimates the cost of quality-adjusted life-year (QALY) per patient. We applied a 20-year horizon (1-year Markov cycles). Cost-effectiveness was expressed in terms of cost per QALY. All costs are presented in 2011 US dollars. Probabilistic sensitivity analyses were conducted. Results: The total cost for the SIR treatment arm over the 20-year duration of the model is estimated to be $136,778. This compares with $142,624 for the TAC treatment arm, resulting in an incremental cost of SIR compared with that of TAC of À$5,846. Over 20 years, SIR was estimated to have 8.18 QALYs compared with 7.33 QALYs for TAC. The resulting incremental utility of SIR compared with that of TAC is 0.84 QALY gained. SIR is estimated to be both less costly and more effective than TAC, indicating that it is the dominant strategy. Notably, results suggest that SIR has a 78% probability of being dominant over the TAC strategy and a 100% probability of having an incremental cost-effectiveness ratio at or below $10,064 (1 GDP) per QALY. Conclusions: These analyses suggest that in the Mexican setting, the use of SIR in place of TAC for the prevention of graft rejection in this population is likely to be cost saving.
Introduction
The worldwide rise in the number of patients with chronic renal disease and subsequent end-stage renal disease (ESRD) is threatening to reach epidemic magnitudes over the next decades [1, 2] . In Mexico, ESRD is a major complication of diabetes and requires dialysis or transplantation for survival. It is estimated that there are 175,729 persons in Mexico with type 2 diabetes and nephropathy (urine albumin/creatinine 4 300 mg/g) [3] . During the last decade, Mexico has experienced growth in its dialysis population. Approximately 25,000 patients currently receive chronic dialysis, with the majority receiving continuous ambulatory peritoneal dialysis [4] .
Renal transplantation is the treatment of choice for ESRD because, if successful, the quality and duration of life is better than that achieved with long-term dialysis [5] [6] [7] [8] [9] . ESRD has not only clinical consequences but also economic implications. Prolonged dialysis and subsequent retransplantation are associated with increased direct and indirect costs that affect both society and individual patients. Total annual costs of treating ESRD patients in Mexico were estimated at US $24,032 per patient and US $15,724 per patient for hemodialysis and peritoneal dialysis, respectively [10] .
Immunosuppressive drugs have been widely used in renal transplantation, providing low rates of rejection and improved graft survival over earlier regimens [11] [12] [13] . Their long-term use is associated with impaired renal function and an increase in cardiovascular risk factors, although some of these risk factors lead to progressive renal dysfunction [14] .
Sirolimus (SIR), which does not have the adverse events associated with calcineurin inhibitors (CNIs), has recently become available for prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants [15] . SIR reduced the incidence of subsequent acute rejection episodes and the need for additional drug therapy in patients experiencing acute rejection. Unlike CNIs, SIR is not nephrotoxic [16] [17] [18] and therefore offers the prospect of improved longer term graft survival while maintaining the improvements in short-term outcomes delivered to date by cyclosporine A (CsA) and tacrolimus (TAC) [19] [20] [21] [22] [23] [24] . Converting patients to SIR earlier, when serum creatinine is lower, leads to significantly greater improvements in renal function [25, 26] .
In view of the growing number of patients in need of treatment and the financial constraints in the Mexican health care system, efficient allocation of scarce resources becomes increasingly important.
The objective of this study was to conduct a computerized cost-effectiveness analysis of SIR versus TAC for the treatment of ESRD. Outcomes and costs were combined to assess the comparative cost-effectiveness of treatment with SIR or TAC for the prevention of graft rejection in renal transplant recipients. Mathematic models were used to assess the comparative effectiveness and cost-effectiveness of alternative treatment strategies. The study results may be used to guide policy decisions, to inform clinicians, or to assist in the design of future clinical studies.
Methods
A cost-utility analysis was conducted by using a Markov model [27, 28] to compare SIR with TAC in the prophylaxis of organ rejection in renal transplant recipients. The population entering the model was assumed to be 40 years of age. These assumptions were based on the average age and weight of patients in the trial (concurrent once-daily versus twice-daily radio therapy (CONVERT) [29] and CONCEPT [30] ). The model was constructed, simulating the natural history of patient with renal transplantation, with four mutually exclusive disease states: rejection free, acute rejection, graft loss, and death. The cycle length for the model was set to 3 months to fully incorporate the effect of therapy on quality of life, and the maximum time horizon was set to 20 years.
The model considers 1) an initial therapy; this is given to all recipients, except where the donor is an identical twin, at the outset of treatment. Therapy is usually triple therapy, using one specific CNI (i.e., CsA or TAC) in combination with a steroid (e.g., prednisolone) and azathioprine, and 2) maintenance therapy; this is the immunosuppression on which patients are maintained long term, essentially the entire duration of the survival of the kidney graft. Often, maintenance therapy is identical to initial therapy, but at a reduced dosage because the transplanted kidney becomes immunologically more stable with increasing time. [31] It is also not uncommon, however, for agents used in maintenance therapy to be altered in response to side effects or the development of acute rejection or chronic allograft nephropathy [32] . The costs of long-term maintenance therapy were included because the analysis was limited to 20 years.
Model Structure
The model, presented in Figure 1 
Input Parameters
The model considers various parameters to estimate total costs, life years, and quality-adjusted life-years (QALYs). Input parameters were taken from a variety of sources including clinical trial data and other published studies [29, 30, [33] [34] [35] [36] . Input parameters such as mortality and clinical efficacy (acute rejection, graft loss, dialysis) were extracted from a variety of sources [9] . Efficacy for treatment regimens was measured as the difference in the risk of acute rejection, graft loss, dialysis, and death between regimens. Disease progression data were derived from a critical review of the literature, previous cost-effectiveness analyses, and an ESRD natural history model recently presented by Morton et al. [37] .
Costs of Treatment
The cost of treating an ERSD in Mexico was obtained from an economic evaluation ''Cost-effectiveness of interventions for endstage renal disease.'' The authors used a cost-effectiveness model to estimate the direct medical costs associated with treating an ESRD. The estimate includes costs of inpatient and outpatient care, monitoring for side effects, prophylaxis, and treatment of side effects and is expressed in 1998 Mexican pesos. Costs were updated to US dollars in 2011 by using the consumer price index for medical care (Table 1) .
Direct medical costs were calculated as the sum of treatment costs, drugs cost, patient management costs, and the cost of complications (visits, hospitalizations, emergency consults, laboratory tests, diagnosis tests, etc.).
Utility Weights
Utility weights were applied from those previously used in an ESRD decision model. These utility values are used to estimate QALYs by multiplying the number of life years within a particular health state by the health state's utility weight. Utility weights by disease severity were obtained from a study by Laupacis et al. [40] in which 0.76 was estimated for a graft functioning, 0.68 for graft loss, and 0.54 for dialysis.
Discounting, Time Horizon, and Perspective
The analysis was taken from the perspective of Mexican publicly funded health care system. In the base-case analysis, the time 
horizon of the model was set to 20 years. Both costs and effects were discounted at a rate of 5% annually [41] .
Incremental Cost-Effectiveness Ratio
In this analysis, both the costs and the health consequences of the alternatives were examined. The effectiveness measure was QALY. The direct comparison between two alternatives was obtained through the incremental cost-effectiveness ratio (ICER). Comparing strategy SIR with strategy TAC, the ICER value represents the relative increment of cost at which a relative unitary increment of benefit could be obtained. The ICER was calculated as follows:
with SIR -QALY gained with TAC
To determine the relative threshold at which treatment became cost-effective, we adopted a willingness-to-pay threshold of 1 GDP per capita per QALY gained as ''cost-effective'' according to the Mexican Guideline for economic evaluation [41] . The GDP for Mexico in 2011 was US $ 10,064 resulting in the threshold of US $10,064. Although this is lower than the 3 GDP per capita as recommended by the WHO per unit of DALY averted [42] as a readily available indicator to derive the following three categories of costeffectiveness: Highly cost-effective (less than GDP per capita); Costeffective (between one and three times GDP per capita); and Not cost-effective (more than three times GDP per capita).
Sensitivity Analysis
Probabilistic sensitivity analysis (PSA) was performed by using Monte Carlo simulation to evaluate the multivariate uncertainty in the model. The input parameters were varied simultaneously over specified ranges. Various probability distributions were chosen on the basis of assumptions for each input parameter. The beta distribution was specified for the probability, utility, and risk reduction parameters. The gamma distribution was specified for the cost parameters. The Monte Carlo simulation drew values for each input parameter and calculated expected cost and effectiveness for each arm of the model. This process was repeated 1000 times to give a range of all expected cost and effectiveness values.
To evaluate uncertainty with respect to model parameters, PSAs with 1000 iterations were conducted for the key parameters for which the greatest uncertainty existed. Therefore, the curve represents the probability that SIR is cost-effective (compared with TAC) at particular cost per QALY thresholds; hence, the term ''acceptability curve. '' In addition, univariate sensitivity analysis was conducted to identify variables that had the largest impact on the model results. For the univariate sensitivity analysis, we varied all parameters shown in Table 2 by Ϯ10%. The parameters that had the largest impact on the model results are presented in a tornado diagram.
Analysis
Because our aim was to inform decision makers on the costeffectiveness of these two approaches of ESRD treatment, we adopted this perspective to perform analyses. We used QALY as an effectiveness measure.
The comparative efficiencies of alternative treatment strategies were measured by the ICER, defined as the additional cost of a specific treatment strategy divided by its additional health benefit, expressed as QALYs gained. If one strategy was more costly and less effective than another strategy, it was considered to be strongly dominated. If a strategy was both less effective and had a higher cost-effectiveness ratio than another strategy, it was considered to be weakly dominated. Table 3 presents the base-case cost-effectiveness results. As shown, the total cost for the SIR treatment arm over the 20-year duration of the model was estimated to be $136,778. This compares with $142,624 for the TAC treatment arm, resulting in an incremental cost of SIR compared with that of TAC of À$5,846. Over 20 years, SIR was estimated to have 8.18 QALYs compared with 7.33 QALYs for TAC. The resulting incremental utility of SIR compared with that of TAC is 0.84 QALY gained. The base case showed that the least costly and more effective strategy was SIR. SIR strategy had an ICER of À$6940 per QALY gained ($/QALY). 
Results
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Sensitivity Analysis
A PSA was performed including all variables in the model (see Table 2 ). The ICER scatter plot of SIR to TAC is shown in Figure 2 for a discount rate of 5%. Each dot represents one simulation. The ICER estimates in the southeast quadrant make up 88% of the simulations and indicate that SIR is less costly and more effective, dominating TAC. The rest of the simulations lie in the northeast quadrant, with 12% below US $10,064 per QALY. Results show that 100% of the observations are cost-effective for a willingness-to-pay threshold of $10,064 (1 GDP) per QALY. PSAs confirmed that the SIR strategy was dominant over TAC in more than 88% of the cases. 2 0 1 2 ) 2 1 1 -2 1 7 The cost-effectiveness acceptability curve shows the probability of SIR being cost-effective compared with TAC in a wide range of willingness-to-pay thresholds (Figure 3 ). Before considering a discount rate of 5%, at a willingness-to-pay threshold of $10,064 per QALY (corresponding to Mexico's GDP for 2011), the SIR strategy had 100% probability of being cost saving.
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Univariate sensitivity analyses are summarized in Figure 4 Over 20 years of follow-up, there was evidence that SIR patients had significantly less mortality rate, more QALY gained, and less dialysis procedures than TAC arm patients (Fig. 5A-D) . The estimated cumulative medical costs at 20 years averaged $136,778 for the SIR arm and $142,624 for the TAC arm (Fig. 5D) . As shown in Figure 5D , costs for TAC increased at a faster rate because of crossover to dialysis therapy.
Discussions
ESRD has a profound financial impact on patients, families, and society as a whole. Most health care systems currently place great importance not only on the efficacy of an intervention but also on its cost. Cost-effectiveness analyses are becoming increasingly important to allow patients, physicians, and payers to evaluate trade-offs between clinical efficacy and financial impacts.
Diabetes is considered to be the leading cause of ESRD in Mexico [43] [44] [45] . There are about 175,729 persons in Mexico with type 2 diabetes and nephropathy (urine albumin/creatinine 4 300 mg/g) [3, 46] . Accordingly, the Latin American Society of Nephrology and Hypertension Annual Report 2002 showed a prevalence of dialysis (both hemodialysis and peritoneal dialysis) and renal transplant of 305 and 72 patients per million population in Mexico, respectively [4, 46] , that is, a total national renal replacement therapy (RRT) prevalence of 377 per million population. In the same report, an acceptance rate of 103 new patients for RRT per million population was reported. These data reflect the limited availability of RRT and the presence of data subregistry in Mexico.
The implications of this study are that SIR should be used preferentially over TAC in subjects who receive a graft following renal failure. As a result, long-term costs are likely to be notably reduced and graft survival and quality of life improved substantially. With limited clinical and economic resources and the magnitude of costs for dialysis and posttransplantation care, the relationship between cost and efficacy (short-term acute rejection and long-term graft survival) of SIR becomes even more important for decision makers to consider.
This study provides evidence for the preferential use of SIR rather than TAC for the primary prevention of graft rejection in patients undergoing RRT in Mexico. The magnitude of dominance of SIR over TAC in Mexico suggests that these estimates are likely to be reflected in analyses elsewhere. A study done in the United Kingdom suggests that SIR may be more cost-effective than TAC for the primary prevention of graft rejection in renal transplant recipients. In this study, SIR was economically ''dominant'' [47] .
SIR reduced acute rejection rates significantly [48, 49] . The Rapamune Maintenance Regimen study has demonstrated improved renal function and blood pressure among kidney transplant patients who had CsA withdrawn early after transplantation [22, 50, 51] .
Despite the growing importance of economic evaluation in informed decision making, few studies have been published to date regarding the economic impact of the different therapeutic strategies for the prophylaxis of graft rejection [52, 53] . In fact, this study is the first to be published in Mexico that assesses the economic value for the Mexican Heal Care System of SIR among kidney transplant patients who had CsA withdrawn early after transplantation.
Over 20 years, SIR was estimated to have 8.18 QALYs compared to 7.33 QALY for TAC. The resulting incremental utility of SIR compared to TAC is 0.84 QALY gained. SIR is estimated to be both less costly and more effective than TAC, indicating that it is the dominant strategy. Notably, results suggest that SIR has a 78% probability of being dominant over the TAC strategy, and a 96% probability of having an incremental cost-effectiveness ratio at or 
below $10,064 (1GDP) per QALY. The classification of cost-effective interventions based on the suggestions from the Commission on Macroeconomics and Health (CMH) (WHO 2001), states that to be considered cost-effective, an intervention has to have a cost-effectiveness ratio of less than three times gross domestic product (GDP) per capita,. However, The WHO also delineates three cost effectiveness thresholds; (i) highly cost effective, defined as lower than the GDP per capita, (ii) cost-effective, defined as one to three times GDP, and (iii) not-cost effective, defined as more than three times the GDP. The GDP for Mexico in 2011 was US $10,064 resulting in the threshold of US $10,064, US $10,064-US $30,192 and 4US $30,192 for the three categories, respectively. Applying the WHO criteria, SIR would be considered as an highly cost-effective intervention [53] . The analysis indicates that treatment with SIR is cost saving compared with TAC treatment. Patients treated with SIR are expected to see a significant improvement in life years and QALYs. Patients treated with SIR are also expected to see a reduction in dialysis procedures and mortality compared with patients treated with TAC. The reduction in expected life years and QALYs for TAC compared with SIR treatment was driven by the higher expected dialysis and mortality rate. Overall, patients receiving SIR were expected to receive the greatest benefit in terms of both graft loss prevention and dialysis.
Limitations
The absence of both long-term outcome and quality of life from trial data makes assessment of the clinical effectiveness and cost-effectiveness of the newer immunosuppressants contingent on modeling based on extrapolations from short-term trial outcomes. The choice of the most appropriate short-term outcome (e.g., acute rejection rate or measures of graft function) for such modeling remains a matter of clinical and scientific debate.
Conclusions
This modeling study demonstrates that prophylaxis treatment with SIR in graft rejection in the Mexican setting is likely to be viewed as good value for money over patient lifetimes. There were benefits in terms of both projected life expectancy and quality-adjusted life expectancy accompanied by cost savings from dialysis avoided and increased treatment and overall total lifetime costs.
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